Cargando…
Multidrug-resistant tuberculosis in COVID-19: Double trouble
COVID-19 pandemic has changed the lives of many especially those living with chronic diseases. India has the highest burden of multidrug resistant tuberculosis (MDR TB) in the world. The pandemic and the lockdown created multiple bottlenecks in the provision of healthcare as well as the distribution...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313087/ https://www.ncbi.nlm.nih.gov/pubmed/34334915 http://dx.doi.org/10.1016/j.mjafi.2021.05.002 |
_version_ | 1783729268513046528 |
---|---|
author | Marwah, Vikas Peter, Deepu K. Ajai Kumar, Tentu Bhati, Gaurav Kumar, Arvind |
author_facet | Marwah, Vikas Peter, Deepu K. Ajai Kumar, Tentu Bhati, Gaurav Kumar, Arvind |
author_sort | Marwah, Vikas |
collection | PubMed |
description | COVID-19 pandemic has changed the lives of many especially those living with chronic diseases. India has the highest burden of multidrug resistant tuberculosis (MDR TB) in the world. The pandemic and the lockdown created multiple bottlenecks in the provision of healthcare as well as the distribution of medications. The stigma of tuberculosis leads to mental trauma, suffering, delay in diagnosis, and non-compliance to therapy. Lockdown imposed due to COVID-19, aggravated the fears of each patient and had made medical care access difficult. Here we describe a patient with MDR TB and chronic hepatitis B and how the course of the disease and its management was affected by COVID-19. |
format | Online Article Text |
id | pubmed-8313087 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-83130872021-07-26 Multidrug-resistant tuberculosis in COVID-19: Double trouble Marwah, Vikas Peter, Deepu K. Ajai Kumar, Tentu Bhati, Gaurav Kumar, Arvind Med J Armed Forces India Case Report COVID-19 pandemic has changed the lives of many especially those living with chronic diseases. India has the highest burden of multidrug resistant tuberculosis (MDR TB) in the world. The pandemic and the lockdown created multiple bottlenecks in the provision of healthcare as well as the distribution of medications. The stigma of tuberculosis leads to mental trauma, suffering, delay in diagnosis, and non-compliance to therapy. Lockdown imposed due to COVID-19, aggravated the fears of each patient and had made medical care access difficult. Here we describe a patient with MDR TB and chronic hepatitis B and how the course of the disease and its management was affected by COVID-19. Elsevier 2021-07 2021-07-26 /pmc/articles/PMC8313087/ /pubmed/34334915 http://dx.doi.org/10.1016/j.mjafi.2021.05.002 Text en © 2021 Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd. |
spellingShingle | Case Report Marwah, Vikas Peter, Deepu K. Ajai Kumar, Tentu Bhati, Gaurav Kumar, Arvind Multidrug-resistant tuberculosis in COVID-19: Double trouble |
title | Multidrug-resistant tuberculosis in COVID-19: Double trouble |
title_full | Multidrug-resistant tuberculosis in COVID-19: Double trouble |
title_fullStr | Multidrug-resistant tuberculosis in COVID-19: Double trouble |
title_full_unstemmed | Multidrug-resistant tuberculosis in COVID-19: Double trouble |
title_short | Multidrug-resistant tuberculosis in COVID-19: Double trouble |
title_sort | multidrug-resistant tuberculosis in covid-19: double trouble |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313087/ https://www.ncbi.nlm.nih.gov/pubmed/34334915 http://dx.doi.org/10.1016/j.mjafi.2021.05.002 |
work_keys_str_mv | AT marwahvikas multidrugresistanttuberculosisincovid19doubletrouble AT peterdeepuk multidrugresistanttuberculosisincovid19doubletrouble AT ajaikumartentu multidrugresistanttuberculosisincovid19doubletrouble AT bhatigaurav multidrugresistanttuberculosisincovid19doubletrouble AT kumararvind multidrugresistanttuberculosisincovid19doubletrouble |